LG
ALXN

Leuthold Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Leuthold Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,084
Closed -$5.82M – 193
2021
Q1 		$5.82M Sell
38,084
-3,493
-8% -$540K 0.73% 43
2020
Q4 		$6.5M Sell
41,577
-2,062
-5% -$265K 0.86% 37
2020
Q3 		$4.99M Sell
43,639
-863
-2% -$93.1K 0.68% 50
2020
Q2 		$5M Sell
44,502
-1,122
-2% -$119K 0.74% 49
2020
Q1 		$4.1M Sell
45,624
-3,657
-7% -$359K 0.74% 44
2019
Q4 		$5.33M Sell
49,281
-1,251
-2% -$134K 0.69% 59
2019
Q3 		$4.95M Buy
+50,532
New +$5.7M 0.65% 59
2016
Q1 		– Sell
-23,274
Closed -$4.44M – 218
2015
Q4 		$4.44M Buy
23,274
+1,017
+5% +$178K 0.47% 93
2015
Q3 		$3.48M Sell
22,257
-3,254
-13% -$594K 0.37% 103
2015
Q2 		$4.61M Buy
25,511
+1,378
+6% +$238K 0.43% 92
2015
Q1 		$4.18M Buy
24,133
+79
+0.3% +$14.3K 0.39% 93
2014
Q4 		$4.45M Buy
+24,054
New +$4.46M 0.44% 86

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Leuthold Group's ALXN Position: Q2 2021 in Review

Leuthold Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 38,084 shares — an estimated $5.82M sold.

Leuthold Group first reported a position in ALXN in Q4 2014 and held it in 12 quarters. The position peaked at $6.5M in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Leuthold Group reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Leuthold Group sold 38,084 Alexion Pharmaceuticals shares in Q2 2021, an estimated $5.82M.
  • Leuthold Group first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Leuthold Group's Alexion Pharmaceuticals position peaked at $6.5M in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Leuthold Group's 13F filing for Q2 2021, filed 13 Aug 2021.